Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy.
OBJECTIVE
To compare the accuracy of two invasive tests, the rapid urease test and histology, one month after antimicrobial treatment of Helicobacter pylori.


METHODS
In the present study the rapid urease test was compared with histology in a group of 232 patients who fulfilled the Maastricht criteria for eradication of H. pylori infection. All patients had one week of triple therapy which included omeprazole b.i.d. and two of three antibiotics (metronidazole, clarithromycin and amoxicillin) b.i.d. One month after antimicrobial therapy, all the patients underwent upper gastrointestinal endoscopy. Two biopsy samples were taken from the antrum and corpus for each test. We used the office rapid urease test, which was previously evaluated, and histology with Giemsa stain.


RESULTS
Concordance between both methods was 94% for antrum biopsies, 97% for corpus biopsies and 96% for pooled data. Kappa values were 0.81 for antrum (95% CI: 0.77-0.85%), 0.87 for corpus (95% CI: 0.83-0.91%) and 0.84 for pooled data (95% CI: 0.80-0.88%). Specificity of the rapid urease test is very high (over 98%), sensitivity is lower, but can be improved, if biopsy specimens are taken from both the corpus and the antrum (to 83.6%).


CONCLUSIONS
The rapid urease test with two biopsies from the antrum and corpus of the stomach is a reliable diagnostic method for evaluation of the success of H. pylori eradication one month after antimicrobial therapy.
Tepes
Bojan
B
Department of Gastroenterology, Medical Centre Rogaska, Rogaska Slatina, Slovenia. bojan.tepes@rogaska-medical.com
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001706:Biopsy; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D011706:Pyloric Antrum / Q000187:drug effects / Q000382:microbiology; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014510:Urease
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D014510:Urease; D017291:Clarithromycin; D009853:Omeprazole